Which medications in the drug class Antitubercular Agents are used in the treatment of Acute Gastritis?

1. Shimony S, Reiss Mintz H, Shvartser Beryozkin Y, Shoham A, Raanani P, Wolach O. Necrotizing hemorrhagic gastritis following acute myeloid leukemia induction with midostaurin: an unexpected complication. Acta Haematol. 2020. 143(1):65-8. [Medline].

2. Chen D, Zhao R, Cao W, et al. Clinical characteristics of cytomegalovirus gastritis: A retrospective study from a tertiary medical center. Medicine (Baltimore). 2020 Jan. 99(5):e18927. [Medline]. [Full Text].

3. Yamamoto S, Sakai Y. Acute gastritis caused by concurrent infection with Epstein-Barr virus and cytomegalovirus in an immunocompetent adult. Clin J Gastroenterol. 2019 Jun. 12(3):274-8. [Medline].

4. Gaffuri P, Espeli V, Fulciniti F, Paone G, Bergmann M. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica. 2019 Sep. 111(3):92-7. [Medline]. [Full Text].

5. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr. 2016 Jan. 62(1):36-42. [Medline].

6. Biecker E. Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. World J Gastrointest Pharmacol Ther. 2015 Nov 6. 6(4):172-82. [Medline].

7. [Guideline] Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, et al. Quality indicators for EGD. Gastrointest Endosc. 2015 Jan. 81 (1):17-30. [Medline]. [Full Text].

8. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010 Oct. 8(10):830-7, 837.e1-2. [Medline].

9. Saltzman JR. Hemostatic spray for the management of gastrointestinal bleeding. Gastroenterol Hepatol (N Y). 2019 Jan. 15(1):40-3. [Medline]. [Full Text].

10. Ali Khan M, Howden CW. The role of proton pump inhibitors in the management of upper gastrointestinal disorders. Gastroenterol Hepatol (N Y). 2018 Mar. 14(3):169-75. [Medline]. [Full Text].

11. Bramhall SR, Mourad MM. Is there still a role for sucralfate in the treatment of gastritis?. World J Meta-Anal. 2020 February 28;. 8(1):1-3. [Full Text].

12. US Food and Drug Administration. Statement alerting patients and health care professionals of NDMA found in samples of ranitidine [news release]. September 13, 2019. Available at https://fda.gov/news-events/press-announcements/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine.

13. US Food and Drug Administration. FDA requests removal of all ranitidine products (Zantac) from the market [news release]. April 1, 2020. Available at https://fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.

14. [Guideline] Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2017 Feb. 112(2):212-39. [Medline]. [Full Text].

15. Nyssen OP, McNicholl AG, Megraud F, et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2016 Jun 28. CD009034. [Medline]. [Full Text].

16. Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond). 2020 Jun. 52(6):381-90. [Medline].

17. Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010 Nov. 32(10):1240-8. [Medline].

18. Drepper MD, Spahr L, Frossard JL. Clopidogrel and proton pump inhibitors--where do we stand in 2012?. World J Gastroenterol. 2012 May 14. 18(18):2161-71. [Medline].

19. Chen CH, Yang JC, Uang YS, Lin CJ. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel. Biopharm Drug Dispos. 2012 Jul. 33(5):278-83. [Medline].

20. Pang J, Wu Q, Zhang Z, et al. Efficacy and safety of clopidogrel only vs. clopidogrel added proton pump inhibitors in the treatment of patients with coronary heart disease after percutaneous coronary intervention: A systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2019 Jun. 23:100317. [Medline]. [Full Text].

21. Andreev DN, Maev IV, Dicheva DT. Efficiency of the inclusion of rebamipide in the eradication therapy for Helicobacter pylori infection: meta-analysis of randomized controlled studies. J Clin Med. 2019 Sep 19. 8(9):1498. [Medline]. [Full Text].

22. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of rebamipide in organic and functional dyspepsia: a systematic review and meta-analysis. Dig Dis Sci. 2018 May. 63(5):1250-60. [Medline].

23. [Guideline] Georgopoulos SD, Michopoulos S, Rokkas T, et al. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol. 2020 Mar-Apr. 33(2):105-24. [Medline]. [Full Text].

24. [Guideline] Centers for Disease Control and Prevention. Tuberculosis (TB): treatment for TB disease. Available at https://cdc.gov/tb/topic/treatment/tbdisease.htm. Reviewed: April 5, 2016; Accessed: July 13, 2020.

25. Sonnenberg A, Genta RM. Inverse association between Helicobacter pylori gastritis and microscopic colitis. Inflamm Bowel Dis. 2016 Jan. 22(1):182-6. [Medline].

26. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006 Nov 15. 24(10):1469-74. [Medline].

27. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol. 2006 Mar. 101(3):488-96. [Medline].

28. Andersen LP. Colonization and infection by Helicobacter pylori in humans. Helicobacter. 2007 Nov. 12 Suppl 2:12-5. [Medline].

29. Beers M, Berkow R, eds. Gastritis. The Merck Manual of Diagnosis and Therapy. 18th ed. 2006. Section 3, Chapter 23. [Full Text].

30. Lee EL, Feldman M. Gastritis and other gastropathies. Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 7th ed. Philadelphia: Saunders; 2002. 810-27.

31. Ford A, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2004 Oct 18. CD003840. [Medline].

32. Gelfand DW, Ott DJ, Chen MY. Radiologic evaluation of gastritis and duodenitis. AJR Am J Roentgenol. 1999 Aug. 173(2):357-61. [Medline].

33. Gisbert JP, Pajares JM. Diagnosis of Helicobacter pylori infection by stool antigen determination: a systematic review. Am J Gastroenterol. 2001 Oct. 96(10):2829-38. [Medline].

34. Haruma K. Helicobacter heilmannii: a spiral shaped organism other than Helicobacter pylori. Intern Med. 1999 Mar. 38(3):217-8. [Medline].

35. Ikenberry SO, Harrison ME, Lichtenstein D, et al. The role of endoscopy in dyspepsia. Gastrointest Endosc. 2007 Dec. 66(6):1071-5. [Medline].

36. Iwakiri Y, Kabemura T, Yasuda D, et al. A case of acute phlegmonous gastritis successfully treated with antibiotics. J Clin Gastroenterol. 1999 Mar. 28(2):175-7. [Medline].

37. Kasper DL, Braunwald E, Fauci A, et al. Gastritis. Harrison's Principles of Internal Medicine: Companion Handbook. 16th ed. McGraw-Hill: 2006. Part 12, Chapter 274.

38. Richieri JP, Pol B, Payan MJ. Acute necrotizing ischemic gastritis: clinical, endoscopic and histopathologic aspects. Gastrointest Endosc. 1998 Aug. 48(2):210-2. [Medline].

39. Soltermann A, Koetzer S, Eigenmann F, et al. Correlation of Helicobacter pylori virulence genotypes vacA and cagA with histological parameters of gastritis and patient's age. Mod Pathol. 2007 Aug. 20(8):878-83. [Medline]. [Full Text].

40. Srivastava A, Lauwers GY. Pathology of non-infective gastritis. Histopathology. 2007 Jan. 50(1):15-29. [Medline].

41. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002 Oct 10. 347(15):1175-86. [Medline].

42. Yamamoto T, Matsumoto J, Shiota K, et al. Helicobacter heilmannii associated erosive gastritis. Intern Med. 1999 Mar. 38(3):240-3. [Medline].

43. Morimoto M, Tamura S, Hayakawa T, et al. Phlegmonous gastritis associated with group A streptococcal toxic shock syndrome. Intern Med. 2014. 53 (22):2639-42. [Medline].

44. Min SY, Kim YH, Park WS. Acute phlegmonous gastritis complicated by delayed perforation. World J Gastroenterol. 2014 Mar 28. 20(12):3383-7. [Medline].

45. Sugano K, Tack J, Kuipers EJ, et al, for the faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep. 64 (9):1353-67. [Medline].

46. Shadifar M, Ataee R, Ataie A, et al. Genetic and molecular aspects of Helicobacter pylori in gastritis, pre- cancerous conditions and gastric adenocrcinoma. Gastroenterol Hepatol Bed Bench. 2015 Spring. 8(Suppl 1):S15-22. [Medline].

47. Marginean MO, Melit LE, Mocanu S, Sasaran V. Ibuprofen, a potential cause of acute hemorrhagic gastritis in children - a case report. J Crit Care Med (Targu Mures). 2018 Oct. 4(4):143-6. [Medline]. [Full Text].

48. Arif SH, Mohammed AA. Acute necrotising gastritis in a 14-year-old girl. BMJ Case Rep. 2019 May 19. 12(5):[Medline].

49. Mahase E. FDA recalls ranitidine medicines over potential cancer causing impurity. BMJ. 2019 Oct 2. 367:l5832. [Medline].

50. FDA Updates and press announcements on NDMA in Zantac (ranitidine). US Food and Drug Administration. Available at https://fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine. Accessed: July 13, 2020.

51. Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond). 2020 Jun. 52 (6):381-90. [Medline].

Sarah El-Nakeep, MD Associate Professor, Gastroentrology and Hepatology Unit, Internal Medicine Department, Faculty of Medicine, Ain Shams University, Egypt

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Vincent W Yang, MD, PhD Simons Chair of Medicine, Professor, Departments of Medicine and Physiology and Biophysics, Renaissance School of Medicine at Stony Brook University

Vincent W Yang, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Gastroenterological Association, American Society for Clinical Investigation, Association of American Physicians

Disclosure: Nothing to disclose.

Waqar A Qureshi, MD, FRCP(UK), FACP, FACG, FASGE Professor of Medicine, Chief of Endoscopy, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

Waqar A Qureshi, MD, FRCP(UK), FACP, FACG, FASGE is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Gwendolyn Sarver

Disclosure: Nothing to disclose.

Mohammad Wehbi, MD Associate Professor of Medicine, Associate Program Director, Department of Gastroenterology, Emory University School of Medicine; Section Chief of Gastroenterology, Atlanta Veterans Affairs Medical Center

Mohammad Wehbi, MD is a member of the following medical societies: American College of Physicians, American Gastroenterological Association, American Medical Association

Disclosure: Nothing to disclose.

Kamil Obideen, MD Assistant Professor of Medicine, Division of Digestive Diseases, Emory University School of Medicine; Consulting Staff, Division of Gastrointestinal Endoscopy, Atlanta Veterans Affairs Medical Center

Kamil Obideen, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Sunil Dacha, MBBS, MD House Staff, Division of Digestive Disease, Emory University School of Medicine

Sunil Dacha, MBBS, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Nicole M Griglione, MD Fellow in Gastroenterology, Department of Medicine, Emory University School of Medicine

Nicole M Griglione, MD is a member of the following medical societies: American Medical Association and Illinois State Medical Society

Disclosure: Nothing to disclose.

Richard H Snyder, MD Vice-Chair, Program Director, Department of Medicine, Norfolk General Hospital; Clinical Associate Professor, Department of Internal Medicine, East Virginia Medical School

Richard H Snyder, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.